

1. Record Nr.	UNINA9910830561803321
Titolo	Disordered pharmaceutical materials // edited by Marc Descamps
Pubbl/distr/stampa	Weinheim, Germany : , : Wiley-VCH Verlag GmbH & Company KGaA, , [2016] ©2016
ISBN	3-527-65269-8 3-527-65272-8 3-527-65271-X 9783527652693
Descrizione fisica	1 online resource (646 p.)
Soggetti	Materials biomèdics Biotecnologia farmacèutica Pharmaceutical biotechnology Biomedical materials
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Title Page; Copyright; Table of Contents; List of Contributors; Chapter 1: Some Facets of Molecular Disorder in Crystalline and Amorphous Pharmaceuticals; 1.1 The Crystal/Amorph Alternative; 1.2 Characteristics of the Disorder in Glass Formers; Acknowledgments; References; Chapter 2: Influence of Disorder on Dissolution; 2.1 Introduction; 2.2 Approaches to Enhance Solubility; 2.3 Measuring the Solubility Advantage of Amorphous Compounds; 2.4 Solid Dispersions; 2.5 Polymer Properties; 2.6 Drug-Polymer Interactions; 2.7 Polymer Concentration; 2.8 Other Formulation Components 2.9 Formulation Variables 2.10 Reliable Measurement of Supersaturation; 2.11 Conclusion; References; Chapter 3: Crystal Imperfections in Molecular Crystals: Physical and Chemical Consequences; 3.1 Introduction; 3.2 General Aspects of Defects in Crystals; 3.3 Role of Imperfections in Reactivity and Stability - Chemistry in the Perfect and Imperfect Lattice; 3.4 Role in Physical Processes; 3.5 Concluding Remarks; References; Chapter 4:

Observation and Characterization of Crystal Defects in Pharmaceutical Solids; 4.1 Introduction; 4.2 Techniques for Characterizing Defects within Crystals  
4.3 Techniques for Characterizing Defects Emergent at Crystal Surfaces  
4.4 Techniques for Quantifying Defect Densities within Crystals; 4.5 The Complementarity of Techniques for Characterizing Defects; 4.6 Summary and Outlook; Acknowledgment; References;  
Chapter 5: "Enantiomeric Disorder" Pharmaceutically Oriented; 5.1 Introduction; 5.2 Introduction and Lexicon of Specific Terms Used among Chiral Molecules and Chiral Molecular Associations; 5.3 Restrictions in Symmetry Operations Inside Crystal Lattices with an Enantiomeric Excess Different from Zero  
5.4 Impact of Chirality on Phase Diagrams and the Gibbs-Scott Phase Rule  
5.5 Competitions between Solid Solutions (Impact of Polymorphism on Solid Solutions) Application: Preferential Enrichment; 5.6 Disorder at Level 3 Multiepitaxy between Enantiomers; 5.7 Conclusion and Perspectives; Acknowledgments; References;  
Chapter 6: Conformational Disorder and Atropisomerism in Pharmaceutical Compounds; 6.1 Premise: Conformational Energy Barriers in Flexible Molecules; 6.2 Conformational Topology and Crystallization of Chain Molecules  
6.3 Conformational Polymorphism and Crystallization of Flexible Molecules  
6.4 Conformational Flexibility of Ring Molecules: Carbohydrates; 6.5 Hindered Conformational Isomerism: Atropisomerism; 6.6 Conclusion; Acknowledgments; References;  
Chapter 7: Tautomerism in Drug Delivery; 7.1 Broadband Dielectric Spectroscopy as a Powerful Tool for Investigating the Tautomerization Process in Condensed Materials; 7.2 Tautomerization Kinetics of Supercooled Pharmaceuticals; Acknowledgment; References;  
Chapter 8: Disorders in Pharmaceutical Polymers; 8.1 Polymers Architectures - Structural Disorders  
8.2 Structural States and Phases Transitions

---